GLP-1 Medication History: FDA Approval Timeline

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Glucagon-like peptide-1 (GLP-1) medications have transformed weight management over the past two decades. The first GLP-1 drug—exenatide (Byetta)—earned FDA approval in 2005 for type 2 diabetes, launching an entirely new class of injectable therapies. Since then, the field has expanded dramatically, with semaglutide emerging as a breakthrough option for both metabolic disease and weight loss after its approval in 2009 for diabetes and 2021 for chronic weight management.

The First GLP-1 Drug and Its FDA Approval Date

Exenatide became the first GLP-1 receptor agonist to reach the market when the FDA approved it on April 29, 2005. Developed for type 2 diabetes management, exenatide mimics the natural hormone glucagon-like peptide-1, which regulates blood sugar and appetite signals in the brain. The approval marked a pivotal moment in endocrinology, introducing a new mechanism of action that differed substantially from older insulin-based and sulfonylurea therapies.

Early clinical trials demonstrated that exenatide lowered blood glucose levels while producing an unexpected benefit: meaningful weight loss in patients taking the medication. This dual benefit—improved glucose control plus reduced body weight—attracted significant medical and commercial attention. The discovery set the stage for a decade of GLP-1 research and development, culminating in newer formulations with greater efficacy and longer dosing intervals.

Semaglutide's Rise as the GLP-1 Standard of Care

Semaglutide, a next-generation GLP-1 agonist, arrived in 2009 under the brand name Victoza for type 2 diabetes treatment. Unlike exenatide, which required twice-daily injections, semaglutide needed only once-weekly dosing—a convenience factor that improved patient adherence. By 2017, semaglutide had become one of the most prescribed GLP-1 options for diabetes, with strong evidence supporting both glucose reduction and cardiovascular benefits.

The weight loss application of semaglutide accelerated after Novo Nordisk launched Wegovy in June 2021, the first GLP-1 explicitly approved by the FDA for chronic weight management in adults. Higher doses of semaglutide (2.4 mg weekly) produced striking results in clinical trials, with participants losing 10–15% of body weight on average. This approval fundamentally shifted how obesity was treated in mainstream medicine, moving from diet-and-exercise-only frameworks to pharmacotherapy-supported approaches.

How GLP-1 Medications Work and Why Dosing Matters

GLP-1 receptor agonists function by binding to GLP-1 receptors throughout the brain, pancreas, and gastrointestinal tract. These receptors trigger three coordinated effects: reduced appetite signals (satiety), slower stomach emptying (delayed gastric transit), and improved insulin secretion when blood glucose rises. The combined result is a natural reduction in calorie intake without the stimulant side effects of older weight loss drugs.

Individual responses to GLP-1 therapy vary significantly based on genetic factors, metabolism, and baseline metabolic health. Some patients achieve meaningful weight loss at lower doses (0.5–1.0 mg weekly), while others require the full 2.4 mg dose for optimal results. PlexusDx's approach recognizes this variability: your dose may need to go up as your body adapts, but your price won't. This commitment ensures patients can titrate safely without financial penalties, starting as low as $149/month for compounded semaglutide injection.

Compounded Semaglutide vs. Brand-Name Alternatives

Brand-name semaglutide products (Ozempic for diabetes, Wegovy for weight loss) can cost $900–$1,300 monthly without insurance coverage. PlexusDx offers compounded semaglutide from licensed 503A compounding pharmacies at a fraction of that cost, starting at $149/month. Compounded medications are prepared by state-licensed pharmacists using pharmaceutical-grade ingredients, following the same manufacturing standards as brand products, though they are not FDA-approved as finished drugs.

Choosing compounded semaglutide does not compromise quality or safety. All PlexusDx medications come from licensed 503A compounding pharmacies—never 503B facilities, which manufacture in bulk for multiple patients. The medications are HSA/FSA eligible and available in all 50 states without insurance requirements or membership fees. For patients seeking personalized dosing guidance, PlexusDx also offers the Precision Peptide Genetic Test ($99 add-on after the first month), which maps 14 metabolic pathways and 150+ genetic insights to optimize treatment selection and dosing strategy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

When was the very first GLP-1 medication approved by the FDA?

Exenatide (Byetta) became the first GLP-1 receptor agonist approved by the FDA on April 29, 2005, for type 2 diabetes. Semaglutide followed in 2009, and later received approval in 2021 specifically for chronic weight management under the brand name Wegovy.

How is compounded semaglutide different from brand-name Ozempic or Wegovy?

Compounded semaglutide contains the same active ingredient (semaglutide) prepared by licensed 503A compounding pharmacies at a significantly lower cost—starting at $149/month with PlexusDx versus $900–$1,300 for brands. Compounded versions are not FDA-approved as finished products but meet strict quality and sterility standards.

Can I use HSA or FSA funds to pay for PlexusDx semaglutide?

Yes. PlexusDx compounded semaglutide injection is HSA/FSA eligible, making it an affordable option for patients with these tax-advantaged accounts. PlexusDx also serves all 50 states without requiring insurance or a membership fee.

What side effects should I expect when starting semaglutide?

The most common side effects include nausea, vomiting, diarrhea, and constipation, especially during dose escalation. These effects typically diminish over 2–4 weeks as your body adjusts. Serious but rare side effects include pancreatitis and gallbladder issues; contact your provider immediately if you develop severe abdominal pain.

How does the PlexusDx Precision Peptide Genetic Test help personalize my treatment?

The Precision Peptide Genetic Test ($99) analyzes 14 metabolic pathways and 150+ genetic insights, including variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to semaglutide and other peptides. Results guide dose selection and predict which compounds may work best for your unique biology.

The Journey of GLP-1 Medications: When Was the First GLP-1 Approved?